南财智讯1月29日电，东方生物发布业绩预亏公告，预计2025年年度实现归属于上市公司股东的净利润 为-5.23亿元；归属于上市公司股东的扣除非经常性损益后的净利润为-5.58亿元。本期业绩变化的主要 原因：（一）主营业务影响：本年度公司主营业务保持稳健的发展，但因各产业技术平台战略发展，整 体培育期间持续投入较大，汇兑损失及利息收入对利润的贡献减少，同时计提资产相关折旧摊销费用， 计提部分资产减值损失等原因，使得2025年度净利润亏损。（二）非经营性损益的影响：报告期内正常 的理财收益。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301363 | 美好医疗 | 32.18 | -5.46% | 18.03万 | 5.96 Z | | 301093 | 不是股份 | 79.99 | -5.17% | 9.73万 | · 7.87亿 | | 688351 | 微电生理 | 24.55 | -5.10% | 9.77万 | 2.43 Z | | 688029 | 南微医学 | 81.25 | -4.96% | 4.46万 | 3.64亿 | | 300753 | 爰朋医疗 | 33.75 | -4.74% | 11.59万 | 3.94亿 | | 688068 | 热景生物 | 147.44 | -4.65% | 2.75万 | 4.05 Z | | 688217 | 睿昂基因 | 31.14 | -4.45% | 1.98万 | 6293.79万 | | 300246 | 宝莱特 | 13.79 | -4.44% | 18.01万 | 2.50亿 | | 688393 | 安必 ...

Group 1 - The core viewpoint of the news is that the recent outbreak of Nipah virus in West Bengal, India, has led to a surge in stock prices of companies involved in nucleic acid and antigen testing in the A-share market, indicating a potential investment opportunity in the healthcare sector [1] - Companies such as Maike Biological (300463.SZ), Zhijiang Biological (688317.SH), and Kaipu Biological (300639.SZ) saw their stock prices hit the daily limit, while others like Wanfu Biological (300482.SZ) and Dongfang Biological (688298.SH) increased by over 10% [1] - The Nipah virus poses a significant health threat with a mortality rate exceeding 40%, and the current situation has raised concerns about the potential for human-to-human transmission, although experts suggest the risk remains low in China [2][3] Group 2 - Nipah virus is classified as a zoonotic disease and has been identified as a priority pathogen by the World Health Organization, highlighting its importance for public health and the potential economic impact on related industries [2] - The virus was first discovered in Malaysia in 1998 and has since caused outbreaks in several countries, leading to significant health and economic consequences, particularly in the pig farming industry [2] - There is currently no specific vaccine or effective treatment for Nipah virus, which relies on supportive care for management, indicating a potential market for future pharmaceutical developments [2]

Group 1 - The core viewpoint of the article highlights a surge in stock prices of companies related to nucleic acid and antigen testing, such as Maike Biological (300463.SZ) and Zhijiang Biological (688317.SH), following reports of Nipah virus infections in India [2] - The Nipah virus has a high mortality rate of over 40% and can cause severe symptoms, including fever, headache, and confusion, raising concerns about its potential spread and the risk of imported cases [2][3] - The Nipah virus, first identified in Malaysia in 1998, has caused significant outbreaks in various countries, leading to serious public health threats and economic losses in the pig farming industry [3] Group 2 - There is currently no specific vaccine or effective treatment for the Nipah virus, with management relying on supportive care [3] - Experts indicate that while the Nipah virus can be transmitted between humans, the risk is low and typically requires close contact with infected individuals or animals [4] - The primary transmission routes include consumption of contaminated fruits or syrups and transmission from bats to pigs, then to humans [4]

Group 1 - The article highlights a significant surge in stock prices of companies involved in nucleic acid and antigen testing, such as Maike Biological (300463.SZ), Zhijiang Biological (688317.SH), and Kaipu Biological (300639.SZ), with some stocks hitting the daily limit and others rising over 10% [3][4]. - The recent outbreak of Nipah virus in West Bengal, India, has led to confirmed cases, including healthcare workers, raising concerns about its potential spread [3][4]. - Nipah virus is classified as a zoonotic disease with a high mortality rate, reaching over 40%, and poses a significant public health threat, especially given its history of outbreaks in various regions [4][5]. Group 2 - Experts indicate that while Nipah virus can be transmitted between humans, the risk remains low in China, as transmission requires very close contact with infected individuals or animals [5]. - The primary transmission routes for Nipah virus include consumption of contaminated fruits or syrups and transmission from bats to pigs, which can then infect humans [5].

Group 1 - The Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers, with nearly 100 individuals under home quarantine [1][2] - The virus has a high fatality rate of over 40%, with some reports indicating rates as high as 75%, and there is currently no effective vaccine or treatment available [2][3] - The outbreak has prompted heightened public health alerts globally, with neighboring countries like Thailand and Nepal increasing their screening and quarantine measures for travelers from India [3] Group 2 - The A-share market saw a surge in stocks related to influenza, virus testing, and vaccines, with several companies hitting their daily price limits [1][4] - Companies like Zhijiang Biology and Hualan Vaccine confirmed they have relevant products but currently lack orders from India, while others like Antu Biology and Shuoshi Biology are actively promoting their technical capabilities in response to the outbreak [4][5] - Some vaccine companies, such as Jindike, have stated they do not have any products related to the Nipah virus, indicating a divergence in market reactions among different sectors [5][6]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

Group 1 - The A-share influenza vaccine sector is experiencing a strong performance, with companies such as Da'an Gene, Hualan Biological Engineering, and Zhijiang Biological reaching their daily limit up [1] - Yongshun Biological has seen an increase of over 10%, indicating positive market sentiment towards the sector [1] - Other companies in the sector, including Dongfang Biological, Biological Shares, Zhongsheng Pharmaceutical, Yiling Pharmaceutical, and Rhine Biological, are also witnessing gains [1]

Group 1 - The core point of the article highlights that Oriental Bio announced the acquisition of multiple medical device product registration certificates, including the "Mycoplasma pneumoniae nucleic acid detection kit" [1] Group 2 - The article also mentions that local state-owned assets are beginning to "bottom fish" in the auction housing market, purchasing over 60 properties in the Nansha District of Guangzhou at prices around 6,000 to 7,000 yuan per unit, while the average listing price for second-hand houses in the same community exceeds 20,000 yuan [1]